1.	Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 to 78 Sponsor: Pharmaceutical / Industry Protocol IDs: MOZ11809, NCT01164475
2.	Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients Phase: Phase III Type: Treatment Status: Completed Age: 18 to 78 Sponsor: Pharmaceutical / Industry Protocol IDs: AMD3100-3101, FHCRC-1985.00, NCT00103610
3.	Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients Phase: Phase III Type: Treatment Status: Completed Age: 18 to 78 Sponsor: Pharmaceutical / Industry Protocol IDs: AMD3100-3102, 2005-003599-39, FHCRC-1986.00, NCT00103662
4.	A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MOZ00808, 2008-000689-21, NCT00838357
5.	Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 to 65 Sponsor: Other Protocol IDs: 03-0349, NCT00241358
6.	Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Other Protocol IDs: 08-0897 / 201105349, NCT00733824
7.	AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 07-0227 / 201011796, NCT00512252
8.	Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 to 60 Sponsor: Other Protocol IDs: 2007-0772, NCT00822770
9.	A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 2 to 18 Sponsor: Pharmaceutical / Industry Protocol IDs: MOZ15609, 2010-019340-40, NCT01288573
10.	AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF Phase: Phase II Type: Treatment Status: Completed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: AMD3100-C201, NCT00396266
11.	AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts Phase: Phase II Type: Treatment Status: Completed Age: 18 to 78 Sponsor: Pharmaceutical / Industry Protocol IDs: AMD31002112, NCT00396331
12.	The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD) Phase: Phase II Type: Treatment Status: Completed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: AMD31002113, NCT00444912
13.	Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). Phase: Phase II Type: Supportive care Status: Completed Age: 18 to 78 Sponsor: Pharmaceutical / Industry Protocol IDs: AMD3100-EU23, EudraCT number: 2006-00424729, NCT00665314
14.	Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies Phase: Phase II Type: Treatment Status: Completed Age: 18 to 65 Sponsor: Other Protocol IDs: 09-0713 / 201103429, NCT00914849
15.	Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: MC0889, NCI-2009-01328, 08-005644, NCT00998049
16.	Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase: Phase I Type: Treatment Status: Completed Age: 18 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: MOZ00207, NCT00694590
17.	Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia Phase: Phase I Type: Treatment Status: Completed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: MOZ04808, NCT00990054
18.	IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML) Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 to 70 Sponsor: Other Protocol IDs: 09-1825 / 201101703, NCT01027923
19.	A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 21 and under Sponsor: Other Protocol IDs: MOZBMT, NCT01068301
20.	Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma Phase: Phase I Type: Treatment Status: Completed Age: 18 to 70 Sponsor: Other Protocol IDs: 08186, NCI-2010-00160, NCT01074060
21.	Long-Term Follow Up Study for AMD3100 Patients Phase: No phase specified Type: Treatment Status: Completed Age: 18 to 78 Sponsor: Other Protocol IDs: 2006-0665, NCT00476294
22.	Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant Phase: No phase specified Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Other Protocol IDs: Pro00014563, NCT00901225
23.	Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization Phase: No phase specified Type: Treatment Status: Completed Age: 18 to 78 Sponsor: Pharmaceutical / Industry Protocol IDs: AMD3100-CUP001, NCT00291811